Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine

References

• Chen X, Zeng Y, Li G, Larmonier N, Graner MW, Katsanis E. Peritransplantation vaccination with chaperone-rich cell lysate induces antileukemia immunity. Biol Blood Marrow Transplant 2006;12:275–83
   PubMed Web of Science ®Google Scholar
• Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol Immunother 2000;49:476–84
   PubMed Web of Science ®Google Scholar
• Graner M, Raymond A, Romney D, He L, Whitesell L, Katsanis E. Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma. Clin Cancer Res 2000;6:909–15
   PubMed Web of Science ®Google Scholar
• Graner MW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 2003;52:226–34
   PubMed Web of Science ®Google Scholar
• Kislin KL, Marron MT, Li G, Graner MW, Katsanis E. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB J 2007;21:2173–84
   PubMed Web of Science ®Google Scholar
• Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, et al. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin Exp Immunol 2007;148:136–45
   PubMed Web of Science ®Google Scholar
• Zeng Y, Feng H, Graner MW, Katsanis E. Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood 2003;101:4485–91
   PubMed Web of Science ®Google Scholar
• Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol Immunother 2006;55:329–38
   PubMed Web of Science ®Google Scholar
• Feng H, Zeng Y, Graner MW, Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Blood 2002;100:4108–15
   PubMed Web of Science ®Google Scholar
• Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 2003;101:245–52
   PubMed Web of Science ®Google Scholar
• Graner MW, Romanoski A, Katsanis E. The ‘peptidome’ of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. Int J Hyperthermia, epub ahead of print. DOI: 10.3109/02656736.2013.793406
   Google Scholar
• Feng H, Zeng Y, Whitesell L, Katsanis E. Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. Blood 2001;97:3505–12
   PubMed Web of Science ®Google Scholar
• Larmonier N, Cantrell J, Lacasse C, Li G, Janikashvili N, Situ E, et al. Chaperone-rich tumor cell lysate-mediated activation of antigen-presenting cells resists regulatory T cell suppression. J Leukoc Biol 2008;83:1049–59
   PubMed Web of Science ®Google Scholar
• Li G, Andreansky S, Helguera G, Sepassi M, Janikashvili N, Cantrell J, et al. A chaperone protein-enriched tumor cell lysate vaccine generates protective humoral immunity in a mouse breast cancer model. Mol Cancer Ther 2008;7:721–9
   PubMed Web of Science ®Google Scholar
• Smith DF, Whitesell L, Katsanis E. Molecular chaperones: Biology and prospects for pharmacological intervention. Pharmacol Rev 1998;50:493–514
   PubMed Web of Science ®Google Scholar
• Zeng Y, Chen X, Larmonier N, Li G, Sepassi M, Marron M, et al. Natural killer cells play a key role in the antitumor immunity generated by chaperone-rich cell lysate vaccination. Int J Cancer 2006;119:2624–31
   PubMed Web of Science ®Google Scholar
• Schon M, Schon MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem 2007;14:681–7
   PubMed Web of Science ®Google Scholar
• Shi C, Xiong Z, Chittepu P, Aldrich CC, Ohlfest JR, Ferguson DM. Discovery of imidazoquinolines with Toll-like receptor 7/8 independent cytokine induction. ACS Med Chem Lett 2012;3:501–4
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012;1:894–907
   PubMed Web of Science ®Google Scholar
• Darieva ZA, Lasunskaia EB, Kipnis TL, Dias Da Silva W. Two BCG vaccine formulations prepared from the same strain with different J774 macrophage activation capacities and patterns of NF-kappaB induction. Int J Mol Med 2000;6:575–80
   PubMed Web of Science ®Google Scholar
• Magno C, Melloni D, Gali A, Mucciardi G, Nicocia G, Morandi B, et al. The anti-tumor activity of bacillus Calmette-Guerin in bladder cancer is associated with an increase in the circulating level of interleukin-2. Immunol Lett 2002;81:235–8
   PubMed Web of Science ®Google Scholar
• Makino M, Mukai T. [Enhanced activation of T lymphocytes by urease-deficient recombinant bacillus Calmette-Guerin producing heat shock protein 70-major membrane protein-II fusion protein]. Nihon Hansenbyo Gakkai Zasshi 2012;81:199–203
   PubMedGoogle Scholar
• Saban MR, Hellmich HL, Simpson C, Davis CA, Lang ML, Ihnat MA, et al. Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins. BMC Cancer 2007;7:204
   PubMed Web of Science ®Google Scholar
• Segawa N, Iwamoto Y, Azuma H, Yamamoto K, Ueda H, Katsuoka Y. [Intravesical BCG therapy for superficial bladder cancer]. Hinyokika Kiyo 1998;44:627–31
   PubMedGoogle Scholar
• Yamada H, Matsumoto S, Matsumoto T, Yamada T, Yamashita U. Murine IL-2 secreting recombinant bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2. J Urol 2000;164:526–31
   PubMed Web of Science ®Google Scholar
• LaRue SM, Withrow SJ, Wykes PM. Lung resection using surgical staples in dogs and cats. Vet Surg 1987;16:238–40
   PubMed Web of Science ®Google Scholar
• Polton GA, Brearley MJ, Powell SM, Burton CA. Impact of primary tumour stage on survival in dogs with solitary lung tumours. J Small Anim Pract 2008;49:66–71
   PubMed Web of Science ®Google Scholar
• McNiel EA, Ogilvie GK, Powers BE, Hutchison JM, Salman MD, Withrow SJ. Evaluation of prognostic factors for dogs with primary lung tumors: 67 cases (1985–1992). J Am Vet Med Assoc 1997;211:1422–7
   PubMed Web of Science ®Google Scholar
• Ogilvie GK, Haschek WM, Withrow SJ, Richardson RC, Harvey HJ, Henderson RA, et al. Classification of primary lung tumors in dogs: 210 cases (1975–1985). J Am Vet Med Assoc 1989;195:106–8
   PubMed Web of Science ®Google Scholar
• Ogilvie GK, Weigel RM, Haschek WM, Withrow SJ, Richardson RC, Harvey HJ, et al. Prognostic factors for tumor remission and survival in dogs after surgery for primary lung tumor: 76 cases (1975–1985). J Am Vet Med Assoc 1989;195:109–12
   PubMed Web of Science ®Google Scholar
• Poirier VJ, Burgess KE, Adams WM, Vail DM. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia. J Vet Intern Med 2004;18:536–9
   PubMed Web of Science ®Google Scholar
• Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat BCR-ABL+ murine leukemia. Int J Cancer 2004;110:251–9
   PubMed Web of Science ®Google Scholar
• Epple LM, Griffiths SG, Dechkovskaia AM, Dusto NL, White J, Ouellette, RJ, et al. Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles. PLoS One 2012;7:e42064
   PubMed Web of Science ®Google Scholar
• Vegran F, Rebucci M, Chevrier S, Cadouot M, Boidot R, Lizard-Nacol S. Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma. PLoS One 2013;8:e55103
   PubMed Web of Science ®Google Scholar
• Velculescu VE, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996;42:858–68
   PubMed Web of Science ®Google Scholar
• Lee CH, Kim WH, Lim JH, Kang MS, Kim DY, Kweon OK. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors. J Vet Sci 2004;5:63–9
   PubMedGoogle Scholar
• Lee CH, Kweon OK. Mutations of p53 tumor suppressor gene in spontaneous canine mammary tumors. J Vet Sci 2002;3:321–5
   PubMedGoogle Scholar
• York D, Higgins RJ, LeCouteur RA, Wolfe AN, Grahn R, Olby N, et al. TP53 mutations in canine brain tumors. Vet Pathol 2012;49:796–801
   PubMed Web of Science ®Google Scholar
• Kirpensteijn J, Kik M, Teske E, Rutteman GR. TP53 gene mutations in canine osteosarcoma. Vet Surg 2008;37:454–60
   PubMed Web of Science ®Google Scholar
• Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group. J Clin Oncol 2008;26:955–62
   PubMed Web of Science ®Google Scholar
• Manjili MH, Henderson R, Wang XY, Chen X, Li Y, Repasky E, et al. Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110. Cancer Res 2002;62:1737–42
   PubMed Web of Science ®Google Scholar
• Manjili MH, Park J, Facciponte JG, Subjeck JR. HSP110 induces ‘danger signals’ upon interaction with antigen presenting cells and mouse mammary carcinoma. Immunobiology 2005;210:295–303
   PubMed Web of Science ®Google Scholar
• Wang XY, Kazim L, Repasky EA, Subjeck JR. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J Immunol 2001;166:490–7
   PubMed Web of Science ®Google Scholar
• Wang XY, Kazim L, Repasky EA, Subjeck JR. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease. Int J Cancer 2003;105:226–31
   PubMed Web of Science ®Google Scholar
• Wang XY, Manjili MH, Park J, Chen X, Repasky E, Subjeck JR. Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. Methods 2004;32:13–20
   PubMed Web of Science ®Google Scholar
• Wang XY, Yi H, Yu X, Zuo D, Subjeck JR. Enhancing antigen cross-presentation and T-cell priming by complexing protein antigen to recombinant large heat-shock protein. Methods Mol Biol 2011;787:277–87
   PubMedGoogle Scholar
• Itoh H, Horiuchi Y, Nagasaki T, Sakonju I, Kakuta T, Fukushima U, et al. Evaluation of immunological status in tumor-bearing dogs. Vet Immunol Immunopathol 2009;132:85–90
   PubMed Web of Science ®Google Scholar
• Sottnik JL, Rao S, Lafferty MH, Thamm DH, Morley PS, Withrow SJ, et al. Association of blood monocyte and lymphocyte count and disease-free interval in dogs with osteosarcoma. J Vet Intern Med 2010;24:1439–44
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J Leukoc Biol 2002;71:907–20
   PubMed Web of Science ®Google Scholar